Premium
Prophylactic oral UFT therapy for superficial bladder cancer
Author(s) -
Kubota Yoshinobu,
Hosaka Masahiko,
Fukushima Shuji,
Kondo Iichiro
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930301)71:5<1842::aid-cncr2820710520>3.0.co;2-2
Subject(s) - medicine , tegafur , urology , randomized controlled trial , oral administration , surgery , bladder cancer , transitional cell carcinoma , cancer , gastroenterology
Background . A randomized prospective trial was performed to determine whether long‐term oral UFT (a 1:4 mixture of tegafur and uracil) (Taiho Pharmaceutical Co., Tokyo, Japan) therapy was effective in preventing the intravesical recurrence of superficial bladder cancer. Methods . A total of 112 patients with newly diagnosed superficial transitional cell carcinoma of bladder (Ta, T1 and G1 or G2) were randomized into a UFT‐treated group (300–400 mg/d for 2 years) and a control group. Results . After a median follow‐up period of 24.5 months, the recurrence rate was 25.7% for the UFT group and 43.3% for the control group ( P = 0.015, logrank test). Side effects of UFT administration were acceptably low. Conclusions . These results suggest that long‐term UFT administration after transurethral resection is effective in preventing the recurrence of superficial bladder cancer.